Cardiac Resynchronization Therapy Efficacy Enhancements (CRTee)

Medtronic

Status: Completed

Conditions: Atrial Fibrillation

Treatments: Device: Conducted AF Response (CAFR); Device: Conducted AF Response Plus (CAFRPlus)

Study type: Interventional

Funder types: Industry

Identifiers

NCT02222818

CRTee

Details and patient eligibility

About

The purpose of this study is to demonstrate that the amount of effective CRT (Cardiac Resynchronization Therapy) pacing during AF (atrial fibrillation) when CAFRPlus (Conducted AF Response Plus) is applied is not inferior to the amount of effective CRT pacing during AF when CAFR (Conducted AF Response) is applied.

Full description

The CRTee study is an IDE, prospective, multi-center, randomized, controlled, crossover clinical study, conducted worldwide and designed to demonstrate that the amount of effective CRT pacing during AF (atrial fibrillation) when CAFRPlus (Conducted AF Response Plus) is applied is not inferior to the amount of effective CRT pacing during AF when CAFR (Conducted AF Response) is applied.

The study will be conducted at up to 30 centers located in the United States, Europe and Middle East and Africa (MEA).

Enrollment: 71 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject is willing to sign and date the study patient Informed Consent form.
• Subject is at least 18 years of age (or older, if required by local law).
• Subject is expected to remain available after enrollment to complete follow-up visits in both arms of the study
• Subject has had a Medtronic Viva or Brava CRT-D device implanted at least 30 days prior to enrollment.
• Subject has history of AF burden, of at least 6 days of at least 4 hours of AF over any 4 week period within the last 90 days as documented in device diagnostic data OR if subject has no atrial lead (therefore no device diagnostic data) but clinical evidence of high AF burden.
• Subject has demonstrated history of being able to complete Left Ventricular Capture Management (LVCM) documented in device data.
• Subject has a documented % V pacing during AF of less than or equal to 97% within 90 days prior to enrollment or within 10 days after enrollment.

Exclusion criteria

• Subject has undergone AV node ablation for treatment of AF.
• Subject has complete or 3rd degree AV block.
• Subject has had an MI within 30 days.
• Subject has medical conditions that limit study participation (per physician discretion).
• Subject is enrolled in one or more concurrent studies that could confound the study results as determined by Medtronic.
• Subject has a limited life expectancy for non-cardiac causes that would not allow completion of the study.
• Subject is pregnant (in the US, all women of child-bearing potential must undergo a pregnancy test within seven days prior to CRTee download).
• Subject meets the exclusion criteria required by local law.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

71 participants in 2 patient groups

Group A: CAFR first

Other group

Description:

Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.

Treatment:

Device: Conducted AF Response (CAFR)

Device: Conducted AF Response Plus (CAFRPlus)

Group B: CAFRPlus first

Other group

Description:

Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.

Treatment:

Device: Conducted AF Response (CAFR)

Device: Conducted AF Response Plus (CAFRPlus)